The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1) – Barbara Gehrett, MD; Joseph Gehrett, MD; Chris Flowers, MD; and Loree Britt – wrote a review of musculoskeletal adverse events of special interest (AESIs) found in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 […]
Report 70: Histopathology Series Part 4c – Autoimmunity: A Principal Pathological Mechanism of COVD-19 Gene Therapy Harm (CoVax Diseases) and a Central Flaw in the LNP/mRNA Platform
This report is Part 4c in a series. It follows Part 1, “Report 56: Autopsies Reveal Medical Atrocities of Genetic Therapies Being Used Against a Respiratory Virus;” Part 2, “Report 58: Part 2 – “Autopsies Reveal Medical Atrocities of Genetic Therapies Being Used Against a Respiratory Virus;” and Part 3, […]
Report 64: Histopathology Series Part 4a – Re-Humanizing Data Using “Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series.”
This report is Part 4a in a series. It follows Part 1, “Report 56: Autopsies Reveal Medical Atrocities of Genetic Therapies Being Used Against a Respiratory Virus;” Part 2, “Report 58: Part 2 – “Autopsies Reveal Medical Atrocities of Genetic Therapies Being Used Against a Respiratory Virus;” and Part 3, […]
Report 53: 77% of Cardiovascular Adverse Events from Pfizer’s mRNA COVID Shot Occurred in Women, as Well as in People Under Age 65. Two Minors Suffered Cardiac Events.
The War Room/DailyClout Pfizer Documents Analysis Project Post-Marketing Group (Team 1) produced a shocking review of the Cardiovascular System Organ Class (SOC) from data in Pfizer document 5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021 (a.k.a., “5.3.6“). 1,403 patients, or 3.3% of the total patient population, […]
Pfizer/BioNTech Trial – A failed yet in depth attempt to reproduce the NEJM & FDA efficacy figures
Study version 1.3, published on 2022-12-09 To view the full version with graphics, please click here. Introduction We review, in this article, a list of problems in the Pfizer/BioNTech C4591001 Trial, which came out in our attempts to reproduce the results provided by the study. Using the sponsor’s data communicated to […]
“170 Patients That Changed Everything” – Spectator | Australia
Few people realise that the Emergency Use Authorisation (EUA) of the Pfizer-BioNTech Covid-19 Vaccine/BNT162b2 was granted on the efficacy data of 170 patients. The 162 who received a placebo and 8 patients who were vaccinated formed the basis of the 95 per cent efficacy claims. There has not been much […]
Report 19: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Team Five: Review of Polack with comments and questions. “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine“ Fernando P. Polack, M.D., Stephen J. Thomas, M.D., Nicholas Kitchin, M.D., Judith Absalon, M.D., Alejandra Gurtman, M.D., Stephen Lockhart, D.M., John L. Perez, M.D., Gonzalo Perez Marc, M.D., Edson D. Moreira, […]
Report 03: Phase 1 /2 Study of COVID-19 RNA Vaccine BNT162b1 in Adults: Key Processes Missing.
Mulligan, Lyke et al. Nature Published online August 12, 2020. Cite this article as: Mulligan, M. J. et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature https://doi.org/10.1038/s41586-020-2639-4 (2020). P1 p2: The authors’ put forth the argument that mRNA in BNT162b1 (Note this series used BNT162b1 […]